Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aspire Biopharma Holdings, Inc. - Warrant (NQ:ASBPW)

0.0211 +0.0008 (+3.94%)
Streaming Delayed Price Updated: 3:28 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,406
Open 0.0214
Bid (Size) 0.0211 (9,100)
Ask (Size) 0.0214 (400)
Prev. Close 0.0203
Today's Range 0.0211 - 0.0215
52wk Range 0.0100 - 0.1200
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements
Via ACCESS Newswire
News headline image
Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record
Via ACCESS Newswire

Performance

YTD
+13.4%
+13.4%
1 Month
+20.6%
+20.6%
3 Month
-29.7%
-29.7%
6 Month
-64.8%
-64.8%
1 Year
-71.3%
-71.3%

More News

Read More
News headline image
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors
Via ACCESS Newswire
News headline image
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements
Via ACCESS Newswire
News headline image
Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Via ACCESS Newswire
News headline image
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit
Via ACCESS Newswire
News headline image
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution
Via ACCESS Newswire
News headline image
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity
Via ACCESS Newswire
News headline image
Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign
Via ACCESS Newswire
News headline image
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces Reverse Stock Split
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)
Via ACCESS Newswire
News headline image
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine
Via ACCESS Newswire
News headline image
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
Via ACCESS Newswire
News headline image
Aspire Biopharma Provides Q3 2025 Business Update
Via ACCESS Newswire
News headline image
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
Via ACCESS Newswire
News headline image
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member
Via ACCESS Newswire
News headline image
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin
Via ACCESS Newswire
News headline image
Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform
Via ACCESS Newswire
News headline image
Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication
Via ACCESS Newswire
News headline image
Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product
Via ACCESS Newswire
News headline image
Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement
Via ACCESS Newswire

Frequently Asked Questions

Is Aspire Biopharma Holdings, Inc. - Warrant publicly traded?
Yes, Aspire Biopharma Holdings, Inc. - Warrant is publicly traded.
What exchange does Aspire Biopharma Holdings, Inc. - Warrant trade on?
Aspire Biopharma Holdings, Inc. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for Aspire Biopharma Holdings, Inc. - Warrant?
The ticker symbol for Aspire Biopharma Holdings, Inc. - Warrant is ASBPW on the Nasdaq Stock Market
What is the current price of Aspire Biopharma Holdings, Inc. - Warrant?
The current price of Aspire Biopharma Holdings, Inc. - Warrant is 0.0211
When was Aspire Biopharma Holdings, Inc. - Warrant last traded?
The last trade of Aspire Biopharma Holdings, Inc. - Warrant was at 02/20/26 03:28 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.